CORRESP Filing
Benitec Biopharma Inc.
Date: Feb. 6, 2026 · CIK: 0001808898 · Accession: 0001193125-26-041308
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293077
Letter
Re: Benitec Biopharma Inc. Registration Statement on Form S-3 (File No. 333-293077) Dear Ms. Dickerson: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-293077) so that it may become effective at 3:00 p.m. Eastern Time on February 10, 2026, or as soon thereafter as practicable.
BENITEC BIOPHARMA INC. 3940 TRUST WAY HAYWARD, CALIFORNIA 94545 February 6, 2026 VIA EDGAR Ms. Jessica Dickerson Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
BENITEC BIOPHARMA INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP BENITEC BIOPHARMA INC. 3940 TRUST WAY HAYWARD, CALIFORNIA 94545 February 6, 2026 VIA EDGAR Ms. Jessica Dickerson Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Benitec Biopharma Inc. Registration Statement on Form S-3 (File No. 333-293077) Dear Ms. Dickerson: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-293077) so that it may become effective at 3:00 p.m. Eastern Time on February 10, 2026, or as soon thereafter as practicable. Very truly yours, BENITEC BIOPHARMA INC. By: /s/ Dr. Jerel Banks Name: Dr. Jerel Banks Title: Chief Executive Officer cc: Matthew S. O’Loughlin, O’Melveny & Myers LLP